Hosted on MSN13h
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...
3 Mid-Cap Stocks That Could Take Off in 2025
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...
Positive Buy Rating on Viking Therapeutics Driven by Promising VK2735 Program Advances
Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay Ahead of the ...
BioSpace3d
Higher Biopharma M&A Activity ‘Almost Inevitable’ in 2025, With Viking as Top Candidate: Analysts
Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...
Should You Buy the Dip on This High-Flying Stock?
It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
BioSpace1d
FDA Proposes Setting Bar for Weight-Loss Therapies as Obesity Space Heats Up
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Seeking Alpha4d
SA Asks: Which biotechs are most likely to be acquired near-term?
As a matter of fact, it is developing dual GLP-1/GIP agonist VK2735 both as an injectable and oral drug for the treatment of obesity. It anticipates beginning a Phase 2 study for oral VK2735 ...